Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Lumito

4.20 SEK

-15.83 %

Less than 1K followers

LUMITO

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-15.83 %
-39.13 %
-40.00 %
-47.50 %
-85.73 %
-95.18 %
-98.93 %
-99.23 %
-98.28 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
14.45M SEK
Turnover
8.33K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7/5
2026

General meeting '26

7/5
2026

Interim report Q1'26

20/8
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Press releaseyesterday

Analyst Group: Analyst Group kommenterar Lumitos pilotstudie med Offspring Biosciences

Lumito
Regulatory press releaseyesterday

Lumito och Offspring Biosciences inleder pilotstudie för att kombinera automatiserade arbetsflöden med högkänslig vävnadsanalys

Lumito
Regulatory press releaseyesterday

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release3/11/2026, 7:00 AM

Analyst Group: Lumito deltar på Analyst Groups och Direkt Studios kapitalmarknadsdag onsdag den 11 mars

Lumito
Regulatory press release3/10/2026, 2:15 PM

Analyst Group publicerar analys av Lumito

Lumito
Regulatory press release3/10/2026, 2:15 PM

Lumito publishes equity research report on Lumito

Lumito
Press release3/10/2026, 11:57 AM

Analyst Group: Aktieanalys på Lumito - Från utveckling till kommersiell uppskalning

Lumito
Regulatory press release3/10/2026, 10:45 AM

Lumito presenterar vid Analyst Groups och Infront Direkt Studios kapitalmarknadsdag

Lumito
Regulatory press release3/10/2026, 10:45 AM

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Lumito
Press release2/20/2026, 3:20 PM

Analyst Group: Analyst Group kommenterar Lumitos bokslutskommuniké 2025

Lumito
Regulatory press release2/20/2026, 7:30 AM

Lumito AB publicerar bokslutskommuniké för 2025

Lumito
Regulatory press release2/20/2026, 7:30 AM

Lumito AB publishes year-end report 2025

Lumito
Regulatory press release2/18/2026, 8:20 AM

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Lumito
Regulatory press release2/18/2026, 8:20 AM

Lumito och Atlas Antibodies ingår strategiskt partnerskap för att främja högupplöst vävnadsavbildning

Lumito
Regulatory press release2/17/2026, 2:00 PM

Inbjudan till webbinarium i samband med Lumito AB:s bokslutskommunike 2025

Lumito
Regulatory press release2/17/2026, 2:00 PM

Invitation to webinar in connection with Lumito AB’s year-end report for 2025

Lumito
Press release2/5/2026, 7:30 AM

Analyst Group: Analyst Group kommenterar Lumitos pilotprojekt samt erhållna ordrar

Lumito
Regulatory press release2/3/2026, 8:40 AM

Lumito inleder pilotprojekt med ledande professor inom urologisk cancerforskning vid Lunds universitet

Lumito
Regulatory press release2/3/2026, 8:40 AM

Lumito initiates pilot project with leading professor in urological cancer research at Lund University

Lumito
Regulatory press release1/30/2026, 2:45 PM

Lumito offentliggör tidplan för sammanläggning av aktier samt omräknade villkor för utestående teckningsoptioner av serie TO7

Lumito
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.